Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.56 |
| ▸ | PIK3R2 | O00459 | 8/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271081 | 0.82 | NR1H2 (0.57) | NR1H2NR1H3PIK3R2ALDH1A1 | |
| SCHEMBL1271806 | 0.76 | NR1H2 (0.45) | NR1H2NR1H3PDE10AALDH1A1 | |
| SCHEMBL13770332 | 0.73 | NR1H2 (0.70) | NR1H2NR1H3PIK3R2 | |
| SCHEMBL1272195 | 0.73 | NR1H2 (0.86) | NR1H2NR1H3 | |
| SCHEMBL1272179 | 0.72 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL1272246 | 0.71 | NR1H2 (0.87) | NR1H2NR1H3 | |
| SCHEMBL1272126 | 0.71 | NR1H3 (0.72) | NR1H2NR1H3 | |
| SCHEMBL1272739 | 0.71 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL5142148 | 0.71 | LMNA (0.44) | NR1H2NR1H3PIK3R2 | |
| SCHEMBL28982431 | 0.70 | HSD17B10 (0.62) | ALDH1A1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034526-A1 | Benzimidazole Compounds | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2231617-A1 | BENZIMIDAZOLE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009086138-A1 | BENZIMIDAZOLE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034526-A1 | Benzimidazole Compounds | NR1H4, NR1H2, NR1H3 | NR1H2 2/4885NR1H3 3/4885PIK3R2 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.